Pyxis Oncology, Inc.
Pyxis Oncology, Inc.（PYXS）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · PYXS · 截至 2026年6月9日
活动摘要
买入笔数
2
P-Purchase only
卖出笔数
3
近12个月
买卖比
0.67
Buy/Sell (by trades)
整体情绪
Pyxis Oncology, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
PYXS 季度内部人买卖趋势
PYXS 内幕交易卖出 · PYXS 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · PYXS CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
PYXS 高管卖出股份 · PYXS 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Mar 24, 2026 | Wadhane Jitendra Prin Fin & Acct Officer | Award | 109,461 | — | Form 4 |
| Apr 14, 2025 | HUMPHREY RACHEL Director | Sale | 1,400 | $1K | Form 4 |
| Apr 17, 2025 | HUMPHREY RACHEL Director | Sale | 200 | $194 | Form 4 |
| Apr 21, 2025 | HUMPHREY RACHEL Director | Sale | 13,896 | $14K | Form 4 |
| Nov 26, 2024 | Connealy Pamela Ann CFO & COO | Purchase | 83,400 | $163K | Form 4 |
| Nov 26, 2024 | Connealy Pamela Ann CFO & COO | Purchase | 5,450 | $11K | Form 4 |
| Jun 7, 2024 | Palani Santhosh Director | Award | 6,000 | — | Form 4 |
| Mar 26, 2024 | Connealy Pamela Ann CFO & COO | Award | 328,710 | — | Form 4 |
| Mar 26, 2024 | FLAVIN JOHN L Director | Award | 35,219 | — | Form 4 |
| Mar 26, 2024 | Cline Darren S Director | Award | 35,219 | — | Form 4 |
| Mar 26, 2024 | Lewis-Hall Freda C Director | Award | 35,219 | — | Form 4 |
| Mar 26, 2024 | Dupont Jakob Director | Award | 38,741 | — | Form 4 |
| Mar 26, 2024 | HUMPHREY RACHEL Director | Award | 38,741 | — | Form 4 |
| Mar 26, 2024 | Wadhane Jitendra SVP, Chief Accounting Officer | Award | 131,484 | — | Form 4 |
| Nov 29, 2023 | Connealy Pamela Ann CFO and COO | Other | 36,949 | $52K | Form 4 |
| Nov 15, 2023 | Wadhane Jitendra CAO | Award | 40,000 | — | Form 4 |
| Sep 28, 2023 | Connealy Pamela Ann CFO and COO | Purchase | 8,000 | $15K | Form 4 |
| Sep 27, 2023 | Wadhane Jitendra CAO | Purchase | 2,500 | $5K | Form 4 |
| Sep 27, 2023 | Connealy Pamela Ann CFO and COO | Purchase | 6,426 | $12K | Form 4 |
| Sep 25, 2023 | Wadhane Jitendra CAO | Purchase | 5,000 | $9K | Form 4 |
| Sep 25, 2023 | Connealy Pamela Ann CFO and COO | Purchase | 12,000 | $20K | Form 4 |
| Sep 22, 2023 | Wadhane Jitendra CAO | Purchase | 2,500 | $4K | Form 4 |
| Sep 22, 2023 | Connealy Pamela Ann CFO and COO | Purchase | 5,000 | $9K | Form 4 |
| Sep 14, 2023 | Sullivan Lara President and CEO · Director | Sale | 100 | $225 | Form 4 |
| Sep 18, 2023 | Sullivan Lara President and CEO · Director | Sale | 8,541 | $18K | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 PYXS 内幕交易
PYXS 内幕交易
Pyxis Oncology, Inc.（PYXS）内幕交易数据来源于公司内部人（包括Wadhane Jitendra (Prin Fin & Acct Officer)）提交的SEC Form 4申报文件。过去12个月内，1位内部人向SEC提交了交易申报。PYXS内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Pyxis Oncology, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
PYXS 内幕交易 · 5个问题Pyxis Oncology, Inc.（PYXS）的内部人包括高管和董事，如Wadhane Jitendra (Prin Fin & Acct Officer)等。过去12个月内，1位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026